The efficacy of immune checkpoint inhibitors in thoracic malignancies

The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of...

Descripción completa

Detalles Bibliográficos
Autores principales: Remon, Jordi, Facchinetti, Francesco, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489136/
https://www.ncbi.nlm.nih.gov/pubmed/34615702
http://dx.doi.org/10.1183/16000617.0387-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489136/
https://www.ncbi.nlm.nih.gov/pubmed/34615702
http://dx.doi.org/10.1183/16000617.0387-2020

Ejemplares similares